Masters Speciality Pharma is pleased to announce its appointment as the R-Pharm US exclusive supplier of IXEMPRA® (ixabepilone) to patients and Health Care Professionals in selected countries worldwide on a named patient basis where IXEMPRA® is not registered.
The medicine received marketing approval from the U.S Food and Drug Administration in 2007 and is registered in major markets globally.
Masters has long standing experience in the supply of unlicensed medicinal products in to countries where an unmet need for the medication exists. Masters regulatory knowledge and logistics capabilities will ensure that Patients requiring treatment with IXEMPRA® may obtain access to this medication in a way that is compliant with applicable country regulations and Good Distribution Practices.
You can find out more about IXEMPRA® at www.ixempra.com
R-Pharm US was established in 2014 as part of the R-Pharm JSC strategy to expand into North and South America. R-Pharm US is a fully integrated specialty pharmaceutical company focused on the development and commercialisation of medicines to treat cancer and chronic immune diseases. The pharmaceutical company is now responsible for all activities surrounding manufacturing, distribution, sales and reimbursement of IXEMPRA®.
Patients and Healthcare Professionals wishing to know more about the availability of Ixempra need to contact Masters Speciality Pharma:
Phone: +44 (0)208 327 0900
Fax: +44 (0)208 327 0901